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T h e  h e a r T  i s  n o T  a  T e r m i n a l l y  
D i f f e r e n T i a T e D  o r g a n
Over the last decade, numerous findings from experimental and clinical studies 
have challenged the paradigm that the heart is a post-mitotic organ and myocytes 
are terminally differentiated cells. Recently, two landmark papers have provided 
compelling evidence in favor of myocardial regeneration. Hsiech et al1 used a model 
of transgenic mice to demonstrate that replacement of adult mammalian cardiomyo-
cytes takes place after injury but not during normal aging. Bergmann et al.2 using 
an elegant method of determining cardiomyocyte age, showed that even in humans, 
cardiomyocytes renew at very low rates, with a gradual decrease over the years (1% 
turnover annually at the age of 25, to 0.45% at the age of 75). Fewer than 50% of 
cardiomyocytes are exchanged during a normal life span. These findings emphasize 
the fact that the body’s innate ability to repair the heart is inadequate to compensate 
for a large myocardial injury.
The ideal cell for myocardial regeneration should be easy to isolate and expand 
in vitro, available as an ‘of the shelf’ product and with differentiation potential. In 
addition, safety (no arrhythmias or tumor formation) should be demonstrated before 
any widespread clinical application. Currently, there is no cell with all these charac-
teristics. However, several cell types, including skeletal myoblasts, bone marrow stem 
cells, adipose tissue mesechymal stem cells, embryonic stem cells and cardiac residing 
progenitor cells, have been used experimentally for myocardial regeneration.3
s k e l e T a l  m y o b l a s T s
Skeletal myoblasts were used very early in cell transplantation studies, due to 
their availability and ease for cell expansion. However, in clinical trials they have 
been proven arrhythmogenic and ineffective. In the randomized MAGIC trial4 the 
intramyocardial implantation of skeletal myoblasts in patients with ischemic heart 
disease and ejection fraction <35% failed to improve heart function and the study 
was terminated early.
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b o n e  m a r r o W  a n D  P e r i P h e r a l 
C i r C U l a T i n g  P r o g e n i T o r  C e l l s
Bone marrow constitutes a source for a variety of progeni-
tor cells like hemangioblasts, mesenchymal and multipotent 
adult progenitor cells.5 In a mouse myocardial infarction mod-
el, Orlic et al6 reported that the injected bone marrow c-kit+ 
stem cells fully differentiated into cardiomyocytes, reduced 
infarct size and improved myocardial function. However, a 
subsequent carefully designed experimental study by Murry 
et al7 showed that the intramyocardially injected bone marrow 
stem cells very rarely, if ever, do they differentiate into cardio-
myocytes, although they are able to improve myocardial func-
tion, presumably through paracrine activity. In an elegantly 
designed study in transgenic animals, Alvarez-dolado et al8 
provided evidence that cell fusion of bone marrow derived 
stem cells with cardiomyocytes was responsible for most of 
these supposedly ‘transdifferentiation’ events.
Bone marrow derived stem cells have been tested exten-
sively in clinical trials. In the randomized REPAIR AMI trial,9 
intracoronary administration of bone marrow mononuclear 
cells was associated with improved recovery of left ventricular 
contractile function in patients after acute myocardial infarc-
tion. Patients with the most severely depressed left ventricular 
ejection fraction (LVEF) derived the greatest benefit.
Many clinical trials have been completed, assessing the 
efficacy of the intracoronary infusion of bone marrow derived 
stem cells or peripheral mononuclear cells in patients with a 
recent myocardial infarction. In a meta-analysis10 patients who 
received intracoronary cell therapy 3 to 7 days after successful 
reperfusion, had a significant, albeit modest, improvement in 
LVEF (3.0% increase [95% confidence interval (CI) 1.9 to 4.1]; 
p <0.001), as well as a reduction in infarct size (-5.6% [95% 
CI -8.7 to -2.5]; p <0.001).
These encouraging but modest benefits may be explained 
by the lack of true transdifferention potential of these cells, 
precluding their engraftment in the heart and synchronization 
with native cardiomyocytes. Furthermore, the percentage of 
long term surviving cells in the host myocardium is small.11
m e s e n C h y m a l  s T e m  C e l l s
Mesenchymal stem cells constitute another attractive stem 
cell population. Mesenchymal stem cells (MSCs) are multipo-
tent cells found in several adult tissues. They do not express 
MHC class II proteins and transplanted allogeneic MSCs 
can be detected in recipients for a long period after delivery, 
indicating a lack of immune recognition and clearance.12
Schuleri et al13 injected intramyocardially autologous bone 
marrow derived mesenchymal stem cells in a swine model, 12 
week post-myocardial infarction. MSCs reduced infarct size 
and increased regional contractility and myocardial blood 
flow. In a phase 1 clinical study using intravenous adminis-
tration of allogeneic MSCs derived from healthy donors, in 
patients after myocardial infarction, Hare et al14 confirmed the 
safety and efficacy of this therapy and reported encouraging 
preliminary findings concerning efficacy.
C a r D i a C  P r o g e n i T o r  s T e m  C e l l s
Several groups have reported the existence of resident car-
diac stem cells that are able to differentiate into the main cardi-
ac cell types (cardiomyocutes, smooth muscle and endothelial 
cells). Messina and colleagues first demonstrated that cardiac 
progenitors cells (CPCs) could be grown directly from cardiac 
tissue and further enriched after going through a tissue culture 
step that involved the formation of spherical aggregates, called 
cardiospheres.15 Extensive research in Eduardo Marban’s lab 
at Johns Hopkins University further advanced this method 
towards clinical translation, by developing a technique for 
expanding cells from these cardiospheres, in order to yield 
a sufficient amount of cardiosphere-derived cells (CdCs) 
with cardiogenic properties. Human CdCs injected into the 
border zone of myocardial infarcts in immunodeficient mice 
engrafted and reduced infarct size.16 Using in vivo imaging 
techniques17 and reporter genes the same group showed that 
only a fraction of the injected cells survive after the first few 
days following their delivery to the myocardium. In addition, 
they demonstrated that augmenting CdC retention resulted 
in greater improvement in cardiac function18.
Johnston et al reported that CdCs administered via the 
intracoronary route were effective in ameliorating left ven-
tricular remodeling after myocardial infarction, in a porcine 
model.19 These encouraging data from the preclinical studies 
with CdCs, lead to a phase I clinical study (NCT00893360), 
which investigates the feasibility and safety of intracoronary 
administration of autologous CdCs, in patients with decreased 
LVEF after myocardial infarction. Efficacy will also be as-
sessed as a secondary end point.
i n D U C e D  P l U r i P o T e n T  s T e m  C e l l s
Embryonic stem cells (ES) are the only cell type that 
fulfills the criteria of a real stem cell: pluripotency and self-
renewal. However, their clinical application encounters severe 
obstacles, including ethical issues regarding their isolation 
from embryos. One way to circumvent these issues is to gener-
ate pluripotent cells directly from somatic cells. Takahashi et 
al20 described a method where over-expression of four tran-
scription factors, characteristic of ES cells, in mouse fibrob-
lasts lead to the generation of ES-like pluripotent stem cells. 
The cells, named induced pluripotent stem (iPS) cells, could 
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be differentiated into cells of all three germ layers including 
cardiomyocytes. Recently, human iPS cells were successfully 
differentiated into cardiomyocytes in vitro.21 However, the 
development of methods for directing differentiation of these 
cells towards the desired cell line is still needed, in order to 
eliminate the danger for teratoma formation.21
C o n C l U s i o n
Cardiac regeneration using stem cells emerges as a novel 
treatment option for heart failure. Clinical applications have 
reported encouraging but modest favorable results, concerning 
cardiac functional recovery. However, many issues need clarifi-
cation. The most appropriate cell type, the optimal number of 
injected cells and time for cell delivery, as well as the mode of 
cell function (differentiation or paracrine mechanism) remain 
to be elucidated. Furthermore, ways to improve cell survival 
and long term engraftment are being sought, in an effort to 
enhance the regenerative capability of the cells. A substantial 
amount of basic, translational and clinical research is still 
needed, in order to take advantage of the full therapeutic 
potential of stem cell treatments for heart failure.
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